コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 such as beta2-adrenergic receptor agonists (beta-agonists).
2 rect prodrug of MB07344, a liver-targeted TR-beta agonist.
3 reating LXRalpha-/- mice with a pan-LXRalpha/beta agonist.
4 per day; 80% were also taking a long-acting beta-agonist.
5 and rapidly reconstituted responsiveness to beta-agonist.
6 owing can be reversed by the inhalation of a beta-agonist.
7 se inhaled corticosteroid plus a long-acting beta-agonist.
8 increasing responsiveness to bronchodilating beta-agonist.
9 of the receptor but reduces the efficacy of beta-agonists.
10 e of inhaled glucocorticoids and long-acting beta-agonists.
11 hallenge testing or test of reversibility to beta-agonists.
12 ls allowed the use of as-needed short-acting beta-agonists.
13 c receptor may not benefit from short-acting beta-agonists.
14 wer requirement for both corticosteroids and beta-agonists.
15 cts of small- and large-particle long-acting beta-agonists.
16 apacity ratios) and greater reversibility to beta-agonists.
17 myocardial infarction and the use of inhaled beta-agonists.
18 d by inhaled corticosteroids and long-acting beta-agonists.
19 led corticosteroids and frequent long-acting beta-agonists.
22 ipants with at least one high-use episode of beta agonist (84 [56%] vs 68 [45%], respectively, relati
23 of beta-adrenergic stimulation although the beta-agonist accelerated the kinetics of the twitch and
27 nhibitory activity and confers a partial TGF-beta agonist activity (growth inhibition but not transcr
29 Tg also exerted a small but significant TGF-beta agonist activity in transcriptional activation of p
30 with cardiovascular disease, to new users of beta-agonists (adjusted OR: 7.32 [95% CI, 2.34 to 22.8])
33 aseline airway responsiveness to the inhaled beta-agonist, albuterol, using changes in maximal expira
34 th muscle cells, the physiological target of beta-agonists, alendronate treatment functionally revers
35 We found that several beta blockers and a beta agonist all traverse the same well-defined, dominan
37 espiratory symptoms should be managed with a beta agonist and short-term treatment of oral steroids,
38 osteroids, >5 prescriptions for short acting beta agonists and more than four visits to a physician f
39 ( approximately 30-90%) increase in maximal beta-agonist and histamine [phosphoinositide (PI) hydrol
41 3 + CD28-stimulated IL-13 production by both beta-agonist and PGE2 was reversed at low agonist concen
43 oncomitant medications included short-acting beta-agonists and a systemic corticosteroid burst for as
44 phil infiltration of the airways, actions of beta-agonists and corticosteroids that alter eosinophil
46 ated with montelukast tended to receive less beta-agonists and have fewer treatment failures than pat
49 ontrolled despite treatment with long-acting beta-agonists and medium-to-high doses of inhaled glucoc
52 h COPD or asthma who were concurrently using beta-agonists and patients with evidence of severe disea
53 r when patients are treated with long-acting beta-agonists and whether such effects are modified by c
54 for atypical infections, fluids, aerosolized beta agonists, and adequate pain control are necessary t
55 ium, 0.92 (CI, 0.88 to 0.96) for long-acting beta-agonists, and 1.05 (CI, 0.99 to 1.10) for theophyll
56 led therapies (anticholinergics, long-acting beta-agonists, and corticosteroids), pulmonary rehabilit
58 et for improving the therapeutic efficacy of beta-agonists, and demonstrate the utility of the unique
59 0.6 (37 degrees C), increased to 16 +/- 1 by beta-agonists, and inhibited to less than 2.0 by amilori
60 tory to inhaled corticosteroids, long-acting beta-agonists, and leukotriene receptor antagonists.
61 ed corticosteroids, ipratropium, long-acting beta-agonists, and theophylline in the 6 months precedin
63 esponsiveness of these phenotypes to inhaled beta-agonist, antimuscarinic, and corticosteroid therapy
70 f treatment with the addition of long-acting beta agonists as the next step if symptoms continue.
71 d corticosteroids (ICSs) with a short-acting beta-agonist as a separate inhaler used when needed for
72 ospitalizations, and (3) use of short-acting beta-agonists as quick-relief (sometimes referred to as
74 in lung function included responsiveness to beta-agonist, baseline FEV(1), methacholine reactivity,
76 modified fused receptor was not activated by beta-agonists but rather by a nonbiogenic amine agonist
77 cells may increase therapeutic responses to beta-agonist by increasing beta(2)AR expression or minim
84 2.47% to 6.78%) increase in FEV1 response to beta-agonist compared with placebo, with no increase in
85 bstantially longer than that of short-acting beta-agonists, compared with ipratropium, an anticholine
94 this approach is to titrate both the ICS and beta-agonist dose according to need and enhance ICS use
96 stradiol, and the specific estrogen receptor-beta agonist DPN, decreased current amplitude measured i
98 t change in PEF, symptoms, and use of rescue beta-agonists during the 425 severe exacerbations that o
99 n whole-cell cAMP accumulation stimulated by beta-agonist (EC(50) and B(max)) concentrations, but sig
100 considered a candidate locus for predicting beta-agonist efficacy in the absence and presence of cor
102 elucidate the molecular mechanisms by which beta-agonists exert anti-inflammatory effects in allerge
107 the efficacy of inhaled corticosteroids and beta agonists for prevention of acute respiratory distre
109 aled anticholinergics or long-acting inhaled beta-agonists for symptomatic patients with COPD and FEV
110 d the safety and efficacy of the long-acting beta-agonist formoterol compared with terbutaline, each
111 We identified 61,712 members who received a beta-agonist from January 1, 1993 to August 31, 1995, in
120 e of inhaled corticosteroids and long-acting beta-agonists in asthma, the lack of efficacy of oral co
122 whether the high doses of corticosteroid and beta agonist increase the risk of adverse effects with b
123 the highly selective estrogen receptor (ER) beta agonist indazole chloride (Ind-Cl) on functional re
124 ose-dependent manner, whereas isoproterenol (beta agonist) induced a dose-dependent decline in prolac
127 ken together, our findings indicate that (1) beta-agonist-induced cardiac injury is associated with a
128 fold) of Hsp20 may protect the heart against beta-agonist-induced cardiac remodeling, associated with
129 responses that were associated with impaired beta-agonist-induced denitrosylation of cardiac ryanodin
131 terenol, which resulted in the inhibition of beta-agonist-induced parotid gland hypertrophy and hyper
132 ot PDE4A or PDE4B, had a major effect on the beta-agonist-induced PDE activation, with only a minimal
135 eezing disorders in baseline as well as post-beta agonist inhalation, and it is significantly reduced
136 Despite pharmacologic therapy with inhaled beta-agonists, inhaled anticholinergics, systemic cortic
137 short-acting beta-agonist or ICS/long-acting beta-agonist inhaler as a reliever rather than regular m
138 ials investigating different combination ICS/beta-agonist inhaler products prescribed according to th
141 s hospitalization and ED visits, six or more beta-agonist inhalers (units) during the prior 6 mo, and
142 er conditions of GRK2 C-terminal expression, beta-agonist inhibition of methacholine-stimulated PI hy
143 an estrogen receptor (ER)-alpha (but not ER-beta) agonist into the dorsal hippocampus rapidly improv
145 recently reported that prolonged exposure to beta-agonists is associated with transient increases in
148 olite and a selective estrogen receptor (ER) beta agonist, is approximately 400x more potent than 17-
149 during systemic infusion of the nonselective beta-agonist isoprenaline (ISO) and compared this with c
151 bnormal automaticity) in the presence of the beta-agonist isoproterenol (0.1 mum; ISO), from 0% to 64
152 ated cells were increased in response to the beta-agonist isoproterenol (contraction: 57.5+/-6.6% ver
156 s to graded brachial artery infusions of the beta-agonist isoproterenol in 41 healthy normotensive Ca
160 bone loss and osteoclast hyperfunction while beta-agonist (isoproterenol) exacerbated those responses
163 hreatening events associated with longacting beta agonist (LABA) use have caused the US Food and Drug
164 rs1042713 (Arg16 amino acid) and long-acting beta-agonist (LABA) exposure for asthma exacerbations in
165 st guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a
168 derate COPD included 2 trials of long-acting beta-agonists (LABAs) (n = 3174), 1 RCT of LABAs and inh
169 The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has be
170 ety concerns surround the use of long-acting beta-agonists (LABAs) for the treatment of asthma, even
178 nic administration of sympathomimetic drugs (beta-agonists) leads to anabolic adaptations in skeletal
179 less than 60% predicted: long-acting inhaled beta-agonists, long-acting inhaled anticholinergics, or
180 y treatment with inhaled corticosteroids and beta agonists may reduce progression to acute respirator
182 st prescription, subjects who had filled one beta-agonist MDI prescription in the 3 mo prior to their
183 that beta-arrestin-2 gene ablation augments beta-agonist-mediated airway smooth muscle relaxation, w
184 PKI and RevAB peptides results in increased beta-agonist-mediated cAMP release, abolishes the inhibi
186 enhanced cAMP production and led to greater beta-agonist-mediated inhibition of basal and TGFbeta-st
187 PKA inhibition eliminates most, if not all, beta-agonist-mediated relaxation of contracted smooth mu
188 ild-type mice resulted in a profound loss of beta-agonist-mediated relaxation of methacholine-contrac
189 ine ASM enabled approximately 30-50% greater beta-agonist-mediated relaxation of methacholine-induced
190 iveness by mitigating both agonist-specific (beta-agonist-mediated) desensitization and cytokine (IL-
191 ids alone or in combination with long-acting beta-agonists might result in improved long-term asthma
193 ipants with at least one high-use episode of beta agonist (more than eight actuations per day of bude
195 did not augment the inhibitory effect of the beta-agonist on mitogen-stimulated increases in ASM grow
197 tein-coupled receptor (GPCR), the effects of beta-agonists on T-cell subtype function remain poorly u
199 decline) or "steroids" (2.7%) as opposed to beta agonists or xanthines (0.8%) or cromolyn without st
200 "prn") use of a combination ICS/short-acting beta-agonist or ICS/long-acting beta-agonist inhaler as
205 nhaled anticholinergics, long-acting inhaled beta-agonists, or inhaled corticosteroids) for symptomat
207 These results establish a mechanism of the beta-agonist paradox and identify a potential asthma mod
208 ll surface expression, but when activated by beta-agonist, partially offsetting the expression phenot
209 ients with COPD or asthma who were not using beta-agonists, patients with COPD or asthma who were con
211 In comparison to subjects who did not fill a beta-agonist prescription, subjects who had filled one b
215 drolone phenylpropionate (Nandrosol) and the beta-agonist ractopamine administration in veal calves,
216 regimen would reduce the risk of overuse of beta agonist, reduce the likelihood of patients to seek
218 (p=0.069) and fewer adverse events requiring beta-agonist rescue (p=0.031) after subcutaneous adminis
221 lar volume (reverse remodeling) and restored beta-agonist response in cardiac muscle from patients wi
224 may be important in delineating variation in beta-agonist responses, especially in African Americans.
225 beta(2)AR function and maximally upregulates beta-agonist-responsive active Na(+) transport by improv
226 ar volume using isolated perfused hearts and beta-agonist responsiveness using muscle strips from pat
228 lts demonstrate the efficacy of short-acting beta-agonist (SABA) delivered by metered-dose inhaler as
229 uidelines recommend that long-acting inhaled beta-agonists should be used as maintenance therapy for
231 isplayed a phenotypic switch, with decreased beta-agonist signaling to adenylyl cyclase and decreased
232 are chronically treated with bronchodilating beta-agonists sometimes experience a worsening of their
234 y smooth muscle relaxation, while augmenting beta-agonist-stimulated cyclic adenosine monophosphate p
235 ediated knockdown of arrestins also augments beta-agonist-stimulated cyclic adenosine monophosphate p
236 GRK2ct, or siRNA-mediated knockdown restored beta-agonist-stimulated inhibition of collagen synthesis
237 PKC alpha in transgenic mice led to impaired beta-agonist-stimulated ventricular function, blunted cy
238 vated in failing CF and was not inhibited by beta-agonist stimulation in contrast to normal controls.
242 intracellular cAMP accumulation mediated via beta-agonist stimulation of the beta-2-adrenergic recept
243 mals, the ability of the heart to respond to beta-agonist stimulation, as measured in the intact anim
249 r(17) phosphorylation and attenuation of the beta-agonist stimulatory effects in perfused mouse heart
250 rine formation results in attenuation of the beta-agonist stimulatory responses in the mammalian hear
252 ine in lung function and increases in use of beta-agonists, systemic corticosteroids, and health care
254 corticosteroids with or without long-acting beta agonists, theophyllines, or leukotriene-receptor an
255 patients with COPD or asthma who were not on beta-agonist therapy (relative risk [RR] = 0.85, 95% con
256 cts of such polymorphisms on the response to beta-agonist therapy have produced inconsistent results.
259 s the gene coding for the receptor target of beta-agonist therapy, the beta2-adrenergic receptor (ADR
261 costeroids in combination with a long-acting beta-agonist, there remains a significant subset of pati
262 nd less than 2 puffs per day of short-acting beta-agonist; they also experienced a lower rate of resp
264 NF-kappaB explained the capacity of PGE2 and beta-agonist to inhibit IFN-gamma but not IL-13 producti
265 isturbances are likely mediated by decreased beta-agonist transduction, increased circulating inflamm
266 s a surrogate biomarker of responsiveness to beta-agonist treatment and childhood asthma severity.
267 the immune system associated with stress or beta-agonist treatment and pave the way for the developm
268 smooth muscle and bronchodilate, but chronic beta-agonist treatment in asthma causes increased sensit
269 declined rapidly following the initiation of beta-agonist treatment in vivo, while laminin B1 and B2
270 djunct therapy or biased ligands may improve beta-agonist treatment of obstructive lung disease.
274 fluticasone plus 50 microg of a long-acting beta-agonist twice daily (LABA step-up), or 100 microg o
279 2 to 3 d; an increase in symptoms and rescue beta-agonist use occurred in parallel, and both the seve
282 reduced asthma symptoms, decreased as-needed beta-agonist use, and improved pulmonary function withou
283 rates in the morning and evening, as-needed beta-agonist use, nocturnal awakenings, asthma-specific
284 of Life Questionnaire-Symptom domain, rescue beta-agonist use, nocturnal awakenings, peak expiratory
285 re was no dose-response relationship between beta-agonists use and risk of myocardial infarction.
286 ic stimulation of the beta2AR by long acting beta-agonists used in the treatment of asthma can promot
288 one or greater with or without a long-acting beta-agonist versus 100 mug or less assigned on at least
289 id, fluticasone furoate, and the long-acting beta agonist, vilanterol could improve survival compared
290 rtmentalized cAMP accumulation stimulated by beta-agonist was assessed by radioimmunoassay and membra
292 ility/relaxation) as a result of infusion of beta-agonist was significantly decreased in all of the m
294 , a nonsteroidal selective estrogen receptor-beta agonist, was tested in the murine listeriosis model
295 inhaled albuterol were assessed after a 2-wk beta-agonist washout period, before administering study
297 -dose inhaled corticosteroids and longacting beta agonists, with two to six exacerbations in the past
298 d an enhanced responsiveness (relaxation) to beta-agonist, with a 60-fold decrease in the ED(50), ind
299 d lymphocytes (PBLs) can respond directly to beta-agonist, with effects including induction of protei
300 ispensing of three or more prescriptions for beta-agonists within the year before enrollment in the s
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。